Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20413292 | 0.96 | TAS1R3 (0.39) | HPGDTLR7TLR8KCNH2TAS1R3 | |
| SCHEMBL15470255 | 0.90 | TLR7 (0.42) | TLR7TLR8KCNH2 | |
| SCHEMBL20413290 | 0.90 | TAS1R3 (0.40) | HPGDTLR7TLR8KDM4EKMT2A | |
| SCHEMBL15470269 | 0.86 | TLR7 (0.44) | TLR7TLR8KCNH2 | |
| SCHEMBL23472376 | 0.85 | HPGD (0.40) | HPGDTLR7TLR8KCNH2TMEM97 | |
| SCHEMBL14376435 | 0.84 | TLR7 (0.42) | HPGDTLR7TLR8 | |
| SCHEMBL20219282 | 0.84 | KCNH2 (0.37) | TLR7TLR8KCNH2 | |
| SCHEMBL15470234 | 0.80 | TLR7 (0.43) | TLR7TLR8KDM4ETAS1R3TAS1R1 | |
| SCHEMBL20219614 | 0.80 | TLR7 (0.43) | TLR7TLR8KDM4ETAS1R3TAS1R1 | |
| SCHEMBL23472178 | 0.78 | HPGD (0.41) | HPGDKDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | HPGD 636/4885TLR7 1000/4885TLR8 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.